News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Aakash Desai: FDA Accelerated Approval of Datopotamab Deruxtecan for EGFRm NSCLC
Aakash Desai/LinkedIn
Jun 24, 2025, 07:38

Aakash Desai: FDA Accelerated Approval of Datopotamab Deruxtecan for EGFRm NSCLC

Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:

“FDA Accelerated Approval Alert – June 23, 2025.

Excited that datopotamab deruxtecan-dlnk (Datroway) has received accelerated approval for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed on prior EGFR-targeted therapy and platinum-based chemotherapy.

This approval is based on pooled data from:

  • TROPION-Lung01 (RCT).
  •  TROPION-Lung05 (single-arm).

With the following outcomes:

  • ORR: 45% (95% CI: 35–54).
  • Median Duration of Response: 6.5 months (95% CI: 4.2–8.4).
  • AE warnings include ILD/pneumonitis, ocular toxicity, stomatitis.

This adds a critical option in the evolving EGFRm NSCLC treatment landscape.”

Aakash Desai: FDA Accelerated Approval of Datopotamab Deruxtecan for EGFRm NSCLC

More posts featuring Aakash Desai on OncoDaily.

Aakash Desai cancer datopotamab deruxtecan FDA NSCLC OncoDaily Oncology
Special Coverage
Blog
Jul 9, 2025, 21:20
Herbert Loong: Sarcomas Are a Group of Rare Diseases Which Benefits From Awareness and Specialist Care
Opinion
Jul 9, 2025, 21:08
Paolo Tarantino Opens the 3rd Annual ADC Toxicity Summit
Insight
Jul 9, 2025, 21:02
Marianna Vitaloni: I'm Incredibly Grateful to the Patients Who Shared Their Stories With Us
Blog
Jul 9, 2025, 20:28
Jennifer Guida: I Had the Privilege to Lead Pioneering Work at the NCI Focused on Cancer Survivorship, Healthy Aging, and Resilience
Blog
Jul 9, 2025, 20:10
Every Person Living with NCDs Such as Cancer Has Access to the Treatment and Care They Need - UICC
Blog
Jul 9, 2025, 19:55
Erythropoietin Promotes an Immunosuppressive Tumor Microenvironment in Liver Cancer Models - NCI Division of Cancer Biology
Blog
Jul 9, 2025, 19:35
UF Health Cancer Center Welcomed Nearly 150 Middle and High School Science Teachers From Across the Southeast
Blog
Jul 9, 2025, 19:16
SIOP Provides Scholarships to Nurses Who Have Insufficient Resources to Participate and to Travel to Our Congress
Blog
Jul 9, 2025, 18:36
2nd Synergies Forum Marks Milestone for Pediatric and Young Adult Cancer Advocacy in Europe - ELLOK
Insight
Jul 9, 2025, 18:16
Akhil Kapoor: We Acknowledge and Appreciate the Trial’s Bold and Innovative Approach in Challenging Established Treatment Paradigms
Blog
Jul 9, 2025, 17:59
Afreen Shariff: Ready to Take Cancer Care to New Heights?
Blog
Jul 9, 2025, 17:48
Adrian Pogacian: New Developments in Scanxiety Live Webinar